| Designation | Number (N = 133) | Percentage | Observation/cost |
| Sex |
|
|
|
| Men | 95 | 71.43% |
|
| women | 38 | 28.6% |
|
| ALT before treatment |
| $8 US | |
| ≥2 ULN | 60 | 45.11% |
|
| ]1 - 2ULN[ | 36 | 27.06% |
|
| normal ALT | 37 | 27.8% |
|
| DNAB before treatment (N = 133) |
| $100 US | |
| >8 log | 8 | 6.01% |
All had DNA ≥ 2000 UI/ml |
| [6 - 8 log[ | 25 | 18.79% | |
| [3 - 6 log[ | 100 | 75.18% | |
| Fibrosis before treatment (N = 44) |
| $130 US | |
| ≥F2 | 26/44 | 59.09% |
|
| Activity before treatment |
|
| |
| ≥A2 | 13/44 | 29.54% |
|
| Molecules used (N = 133) |
|
| |
| Lamivudine | 14 | 10.52% | 12 patients had resistance after 4 years |
| Ténofovir | 112 | 84.21% | $6 US/month via HIV program |
| Atripla® | 7 | 5.26% | Co-infected HIV/HBV |
| Liver ultrasound (N = 133) |
| $20 US | |
| Normal | 98 | 73.68% |
|
| Liver steatosis | 11 | 8.27% |
|
| Cirrhosis | 19 | 14.28% |
|
| micronodular liver | 4 | 3% |
|
| HCC | 1 | 0.7% | Co-infected HIV/VHB |
| Fibroscan (N = 10) |
| Acsess in EUROPE | |
| <8 Kpa | 8 | 80% |
|
| 8.8 Kpa | 1 | 10% |
|
| 26.3 Kpa | 1 | 10% |
|